Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PAF-acetylhydrolase - ICOS Corporation

Next Previous
X
Search
Drug Profile

PAF-acetylhydrolase - ICOS Corporation

Alternative Names: Epafipase; PAF-AH; Pafase; Platelet-activating factor acetylhydrolase; Recombinant human platelet-activating-factor acetylhydrolase; rPAF-AH; SUN Y7016

Latest Information Update: 25 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ICOS Corporation
  • Class Anti-infectives; Anti-inflammatories
  • Mechanism of Action Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Allergic asthma; Inflammatory bowel diseases; Necrotising enterocolitis; Pancreatitis; Reperfusion injury; Sepsis; Type 1 diabetes mellitus

Most Recent Events

  • 08 Mar 2004 A study has been added to the adverse events and Bacterial Infections therapeutic trials sections
  • 23 Dec 2002 Discontinued - Phase-I for Sepsis in Japan (Injection)
  • 23 Dec 2002 Discontinued - Phase-II for Adult respiratory distress syndrome in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top